Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab IV Long-term Safety in Pediatric UC or CD
NCT05442567Phase 3Recruiting
- Sponsor
- Takeda
- Start
- May 2023
- Primary completion
- Feb 2033
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of vedolizumab in ulcerative colitis (UC), Crohn's disease, sponsored by Takeda. Started May 2023; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT05442567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05442567.